close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

16.12 -0.15 (-0.92%)
Streaming Delayed Price Updated: 11:07 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
From Novocure
Via Business Wire
News headline image
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
News headline image
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
From Novocure
Via Business Wire
News headline image
Earnings Scheduled For July 24, 2025 ↗
 
Via Benzinga
News headline image
NovoCure Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Top 3 Health Care Stocks That May Explode In July ↗
 
Via Benzinga
News headline image
NovoCure Q2 Revenue Jumps 6 Percent ↗
Via The Motley Fool
Topics World Trade
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NovoCure's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Novocure: Steady Ahead of Key Milestones ↗
Via The Motley Fool
News headline image
Novocure Reports Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
From Novocure
Via Business Wire
News headline image
Novocure to Report Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Demystifying NovoCure: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗
 
Via Benzinga
News headline image
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial ↗
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial. 
Via Benzinga
News headline image
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
News headline image
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street ↗
Via The Motley Fool
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
News headline image
Why NovoCure Stock Skyrocketed This Week ↗
Via The Motley Fool
Topics Earnings Stocks
News headline image
Why NovoCure Stock Leaped 4% Higher Today ↗
Via The Motley Fool
News headline image
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 ↗
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs. 
Via Benzinga
Topics World Trade
News headline image
NovoCure Surpasses Q1 Expectations ↗
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Novocure Reports First Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.